Detalhe da pesquisa
1.
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Lancet Oncol
; 20(12): 1730-1739, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727538
2.
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.
Nat Commun
; 15(1): 1828, 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418825
3.
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition.
Clin Cancer Res
; 27(16): 4610-4623, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34083234
4.
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Eur Urol
; 75(6): 940-947, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30591354